Cellular Biomedicine Group Inc. (NASDAQ:CBMG)
(“CBMG” or the “Company”), a clinical-stage biomedicine firm engaged in
the development of effective immunotherapies for cancer and stem cell
therapies for degenerative diseases, is pleased to announce the signing
of a ten-year lease of a 113,038 square feet building located in the
“Pharma Valley” in Shanghai Zhangjiang High-Tech Park. The new GMP
facility that will be built on these premises will consist of 40,000
square feet dedicated to advanced cell manufacturing. By the end of
2017, the Company anticipates that the new Zhangjiang, an expanded Wuxi,
and Beijing GMP facilities combined will have 70,000 square feet, and
the Company expects that it will be capable of supporting simultaneous
clinical trials for five different CAR-T and stem cell products, or
approximately the ability to treat 10,000 cancer patients and 10,000
stem cell patients per year.
“We are very
excited to continue to add to our in-house manufacturing capabilities.
This new development, once built out, will substantially expand our
total production facility’s square footage across three key cities in
China. In conjunction with the upcoming expanded GMP facility in Wuxi
for clinical grade Plasmid and Viral Vectors bank production, we will
have an integrated Chemistry, Manufacturing, and Controls (“CMC”)
process for CAR-T production through predominately closed and automated
systems. We believe this will enable us to serve scaled-up demand for
our current and future CAR-T clinical studies and will allow CBMG to
move quickly and efficiently from R&D into manufacturing of CAR-T
cells for clinical use, IND filings, and future commercialization,” said
Tony (Bizuo) Liu, Chief Executive Officer of CBMG.
CBMG
recently announced the approval and commencement of patient enrollment
in China for its CARD-1 Phase I clinical trial utilizing its optimized
proprietary C-CAR011 construct of CD19 chimeric antigen receptor T-cell
(CAR-T) therapy for the treatment of patients with refractory Diffuse
Large B-cell Lymphoma (DLBCL) as well as announcing promising interim
3-month safety data from its Phase I clinical trial in China for
AlloJoin™ off-the-shelf allogeneic stem cell therapy for Knee
Osteoarthritis (KOA).
About Cellular Biomedicine Group (CBMG)
Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of cancer and degenerative diseases. Our immuno-oncology and stem cell projects are the result of research and development by CBMG’s scientists and clinicians from both China and the United States. Our GMP facilities in China, consisting of twelve independent cell production lines, are designed and managed according to both China and U.S. GMP standards. To learn more about CBMG, please visit: www.cellbiomedgroup.com
Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of cancer and degenerative diseases. Our immuno-oncology and stem cell projects are the result of research and development by CBMG’s scientists and clinicians from both China and the United States. Our GMP facilities in China, consisting of twelve independent cell production lines, are designed and managed according to both China and U.S. GMP standards. To learn more about CBMG, please visit: www.cellbiomedgroup.com
No comments:
Post a Comment